Published in Arthritis Res Ther on May 05, 2006
Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nat Rev Immunol (2010) 3.56
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
Adenosine production by human B cells and B cell-mediated suppression of activated T cells. Blood (2013) 1.70
B-cell-depletion therapy in SLE--what are the current prospects for its acceptance? Nat Rev Rheumatol (2009) 1.35
Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol (2010) 1.21
Rituximab therapy in nephrotic syndrome: implications for patients' management. Nat Rev Nephrol (2013) 1.18
Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol (2009) 1.10
The pathology of T cells in systemic lupus erythematosus. J Immunol Res (2014) 1.08
Effect of arsenic on regulatory T cells. J Clin Immunol (2009) 1.07
B-cell depletion in the treatment of lupus nephritis. Nat Rev Nephrol (2012) 1.05
Minimal change disease: a "two-hit" podocyte immune disorder? Pediatr Nephrol (2010) 1.04
B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther (2013) 0.99
The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol Int (2007) 0.98
B-cell-targeted therapies in systemic lupus erythematosus. Cell Mol Immunol (2013) 0.97
Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol (2008) 0.97
Is rituximab effective in childhood nephrotic syndrome? Yes and no. Pediatr Nephrol (2013) 0.92
Association of intrarenal B-cell infiltrates with clinical outcome in lupus nephritis: a study of 192 cases. Clin Dev Immunol (2012) 0.88
Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy. PLoS One (2014) 0.87
Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches. J Biomed Biotechnol (2010) 0.85
Understanding lupus nephritis: diagnosis, management, and treatment options. Int J Womens Health (2012) 0.85
Changes in hepatitis C virus antibody titer and viral RNA load in non-Hodgkin's lymphoma patients after rituximab chemotherapy. Int J Lab Hematol (2008) 0.85
Hepatitis C virus reactivation in cancer patients in the era of targeted therapies. World J Gastroenterol (2014) 0.84
Rituximab administration and reactivation of HBV. Hepat Res Treat (2010) 0.83
B cells and progressive multifocal leukoencephalopathy: search for the missing link. Front Immunol (2015) 0.82
Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis. J Zhejiang Univ Sci B (2012) 0.82
Hepatitis B virus reactivation with rituximab-containing regimen. World J Hepatol (2013) 0.81
Biomarkers and updates on pediatrics lupus nephritis. Rheum Dis Clin North Am (2013) 0.80
Treatment of proliferative lupus nephritis: a slowly changing landscape. Nat Rev Nephrol (2010) 0.79
Genetics of Lupus Nephritis: Clinical Implications. Semin Nephrol (2015) 0.78
Long-term efficacy of anti-CD20 antibodies in refractory lupus nephritis. Rheumatol Int (2011) 0.78
Acute and chronic B cell depletion disrupts CD4+ and CD8+ T cell homeostasis and expansion during acute viral infection in mice. J Immunol (2014) 0.78
Impact of Immune-Modulatory Drugs on Regulatory T Cell. Transplantation (2016) 0.77
Indications for use and safety of rituximab in childhood renal diseases. Pediatr Nephrol (2012) 0.77
Safety and efficacy of rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece. Rheumatol Int (2011) 0.76
Diffuse alveolar hemorrhage: a rare life-threatening condition in systemic lupus erythematosus. Case Rep Pulmonol (2012) 0.75
Treatment of vitiligo with a chimeric monoclonal antibody to CD20: a pilot study. Clin Exp Immunol (2013) 0.75
Developments in lupus 2006. Arthritis Res Ther (2007) 0.75
Monoclonal Antibodies for Systemic Lupus Erythematosus (SLE). Pharmaceuticals (Basel) (2010) 0.75
A distinct lymphocyte distribution in relapse after rituximab for steroid-dependent nephrotic syndrome. CEN Case Rep (2012) 0.75
Treatment of active lupus nephritis with the novel immunosuppressant 15-deoxyspergualin: an open-label dose escalation study. Arthritis Res Ther (2011) 0.75
Overview of pathophysiology and treatment of human lupus nephritis. Curr Opin Rheumatol (2016) 0.75
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol (1995) 29.42
Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med (2004) 8.98
Regulatory T cells in the control of immune pathology. Nat Immunol (2001) 6.98
Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med (2004) 6.48
CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity (1995) 5.77
Regulatory T cells and mechanisms of immune system control. Nat Med (2004) 4.23
Systemic lupus erythematosus. N Engl J Med (1994) 3.35
B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum (2004) 3.35
Type 1 T regulatory cells. Immunol Rev (2001) 3.26
Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum (2005) 3.25
Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol (2000) 3.05
Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med (1995) 2.89
Quantification of regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun (2003) 2.81
CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum (2003) 2.68
An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum (2002) 2.54
CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther (2004) 2.25
Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum (2004) 2.23
Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab. Rheumatology (Oxford) (2004) 2.19
Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc Natl Acad Sci U S A (2003) 2.14
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis (2004) 2.06
The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum (2003) 2.02
Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus. Scand J Immunol (2004) 1.92
The central and multiple roles of B cells in lupus pathogenesis. Immunol Rev (1999) 1.88
B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) (2005) 1.83
B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum (2005) 1.71
Regulatory/suppressor T cells in health and disease. Arthritis Rheum (2004) 1.65
Immune cells and cytokines in systemic lupus erythematosus: an update. Curr Opin Rheumatol (2005) 1.65
Cutting edge: deficiency in the E3 ubiquitin ligase Cbl-b results in a multifunctional defect in T cell TGF-beta sensitivity in vitro and in vivo. J Immunol (2006) 1.62
Abnormal T cell signal transduction in systemic lupus erythematosus. Arthritis Rheum (2002) 1.62
The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J Immunol (1985) 1.57
Specific suppression of T helper alloreactivity by allo-MHC class I-restricted CD8+CD28- T cells. Int Immunol (1998) 1.44
The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol (1985) 1.42
Rituximab: mechanism of action and resistance. Semin Oncol (2002) 1.40
Impairment of CD8+ T suppressor cell function in patients with active systemic lupus erythematosus. J Immunol (2001) 1.36
MRL/Mp CD4+,CD25- T cells show reduced sensitivity to suppression by CD4+,CD25+ regulatory T cells in vitro: a novel defect of T cell regulation in systemic lupus erythematosus. Arthritis Rheum (2005) 1.32
T-regulatory 1 cells: a novel subset of CD4 T cells with immunoregulatory properties. J Allergy Clin Immunol (2000) 1.29
T- and B-cell abnormalities in systemic lupus erythematosus. Crit Rev Immunol (2005) 1.27
Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus (2003) 1.08
B cell depletion in autoimmune disease. Arthritis Res Ther (2003) 1.03
The distinctive specificity of antigen-specific suppressor T cells. Immunol Today (1991) 0.99
Mechanism of action of rituximab. Anticancer Drugs (2002) 0.98
Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand J Rheumatol (2004) 0.97
Protein kinase C-theta mediates a selective T cell survival signal via phosphorylation of BAD. J Immunol (2001) 0.95
B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis. Rheumatology (Oxford) (2005) 0.93
Immune effects of therapy with Adalimumab in patients with rheumatoid arthritis. Clin Exp Immunol (2005) 0.91
Anti-CD20 therapy in systemic lupus erythematosus: a step closer to the clinic. Arthritis Rheum (2005) 0.82
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med (2006) 5.03
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet (2008) 3.00
Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis (2011) 2.13
Regulatory T cells in patients with systemic lupus erythematosus. J Autoimmun (2006) 1.83
Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum (2008) 1.73
Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum (2012) 1.59
Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto's thyroiditis. J Clin Endocrinol Metab (2009) 1.45
Invasive fungal infections in patients with systemic lupus erythematosus. J Rheumatol (2012) 1.44
Detection of periodontal bacterial DNA in serum and synovial fluid in refractory rheumatoid arthritis patients. J Clin Periodontol (2009) 1.25
Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum (2010) 1.24
Molecular cues guiding inflammatory responses. Cardiovasc Res (2010) 1.19
Influence of human cytomegalovirus infection on the NK cell receptor repertoire in children. Eur J Immunol (2010) 1.17
Regulatory T cells in human autoimmune thyroid disease. J Clin Endocrinol Metab (2006) 1.14
Neuropsychiatric manifestations of systemic lupus erythematosus. J Rheumatol (2013) 1.09
Are steroids required for induction therapy and relapses in lupus nephritis? Ann Rheum Dis (2013) 1.06
Functional role of P-selectin glycoprotein ligand 1/P-selectin interaction in the generation of tolerogenic dendritic cells. J Immunol (2007) 1.04
Correlation between pH and irritant effect of cleansers marketed for dry skin. Int J Dermatol (2002) 1.02
CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis. J Clin Immunol (2011) 1.02
Expression of CD64 as a potential marker of neonatal sepsis. Pediatr Allergy Immunol (2002) 1.02
F-actin-binding protein drebrin regulates CXCR4 recruitment to the immune synapse. J Cell Sci (2010) 1.00
DDT-induced oxidative damage in human blood mononuclear cells. Environ Res (2005) 0.97
Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study. Ann Rheum Dis (2012) 0.96
DDT induces DNA damage in blood cells. Studies in vitro and in women chronically exposed to this insecticide. Environ Res (2004) 0.92
Impact of early developmental arsenic exposure on promotor CpG-island methylation of genes involved in neuronal plasticity. Neurochem Int (2011) 0.91
DDE-induced apoptosis in children exposed to the DDT metabolite. Sci Total Environ (2006) 0.88
Expression and function of dectin-1 is defective in monocytes from patients with systemic lupus erythematosus and rheumatoid arthritis. J Clin Immunol (2012) 0.88
Rheumatoid arthritis and the role of oral bacteria. J Oral Microbiol (2010) 0.87
The association of the angiopoietin/Tie-2 system with the development of metastasis and leukocyte migration in neuroendocrine tumors. Endocr Relat Cancer (2010) 0.86
Comparative and prospective study of different immune parameters in healthy subjects at risk for tuberculosis and in tuberculosis patients. Clin Diagn Lab Immunol (2002) 0.85
Expression and function of the P2X(7) purinergic receptor in patients with systemic lupus erythematosus and rheumatoid arthritis. Hum Immunol (2010) 0.82
Serum levels of angiogenic molecules in autoimmune thyroid diseases and their correlation with laboratory and clinical features. J Clin Endocrinol Metab (2009) 0.82
IgG4 (IgG4-RD) related diseases, with a horizon not limited to Mikulicz's disease. Reumatol Clin (2013) 0.82
Effect of fluoride exposure on different immune parameters in humans. Immunopharmacol Immunotoxicol (2010) 0.82
Analysis of expression and function of the inhibitory receptor ILT2 in lymphocytes from patients with autoimmune thyroid disease. Eur J Endocrinol (2011) 0.81
Effect of pentoxifylline on polarization and migration of human leukocytes. J Leukoc Biol (2002) 0.81
The His155Tyr (489C>T) single nucleotide polymorphism of P2RX7 gene confers an enhanced function of P2X7 receptor in immune cells from patients with rheumatoid arthritis. Cell Immunol (2012) 0.81
DDT induces apoptosis in human mononuclear cells in vitro and is associated with increased apoptosis in exposed children. Environ Res (2004) 0.81
Plasmacytoid dendritic cells in patients with autoimmune thyroid disease. J Clin Endocrinol Metab (2013) 0.81
Induction of Th17 lymphocytes and Treg cells by monocyte-derived dendritic cells in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Dev Immunol (2013) 0.81
T cell aggregation induced through CD43: intracellular signals and inhibition by the immunomodulatory drug leflunomide. J Leukoc Biol (2003) 0.80
A male patient with cavitary pulmonary disease. Reumatol Clin (2012) 0.79
[Recommendations for the medical treatment of rheumatoid arthritis]. Rev Invest Clin (2006) 0.79
Pattern of expression of apoptosis and inflammatory genes in humans exposed to arsenic and/or fluoride. Sci Total Environ (2009) 0.79
Rolipram inhibits polarization and migration of human T lymphocytes. J Invest Dermatol (2003) 0.79
Defective expression and function of the ILT2/CD85j regulatory receptor in dendritic cells from patients with systemic lupus erythematosus. Hum Immunol (2013) 0.78
[Treatment guidelines for ankylosing spondylitis and its effect on Mexican rheumatology]. Gac Med Mex (2009) 0.78
[Guidelines in RA treatment: concepts on safety and recommendations using anti-TNF-alpha inhibitors. Grupo de Estudio de Nuevas Terapias de Enfermedades reumáticas (GENTE)]. Rev Invest Clin (2009) 0.78
[Calciphylaxis, renal failure and gout. A patient with hyperuricemia as a risk factor for death]. Rev Med Inst Mex Seguro Soc (2013) 0.78
Effect of polychlorinated biphenyls 118 and 153 on Th1/Th2 cells differentiation. Immunopharmacol Immunotoxicol (2012) 0.78
Abnormal expression and function of Dectin-1 receptor in type 2 diabetes mellitus patients with poor glycemic control (HbA1c>8%). Metabolism (2012) 0.78
Lack of involvement of P-glycoprotein (P-gp) in pemphigus patients with poor response to steroid therapy. J Dermatol Sci (2002) 0.77
Identification of differential expressed transcripts in cervical cancer of Mexican patients. Tumour Biol (2011) 0.77
Expression and functional role of HLA-G in immune cells from patients with systemic lupus erythematosus. J Clin Immunol (2010) 0.77
Participation of N-methyl-D-aspartate receptors on methylmercury-induced DNA damage in rat frontal cortex. Toxicology (2005) 0.77
Serum cystatin C as a marker of renal function in patients with systemic lupus erythematosus. Reumatol Clin (2012) 0.77
Variability in DDT-induced apoptosis in Mexican indigenous populations. Toxicol Mech Methods (2011) 0.76
Should tuberculin skin test be positive to give latent tuberculosis treatment before tumor necrosis factor-alpha inhibitors in selected patients in developing countries? J Rheumatol (2010) 0.76
Hyperglycemia and methylprednisolone: comment on the article by den Uyl et al. Arthritis Rheum (2012) 0.76
Specific therapy to regulate inflammation in rheumatoid arthritis: molecular aspects. Immunotherapy (2014) 0.76
Concomitant therapy with statins and immunosuppressive agents in childhood primary angiitis of the central nervous system: comment on the article by Cellucci et al. Arthritis Rheum (2012) 0.75
Severe and unresponsive HIV-associated alopecia areata successfully treated with thalidomide. Acta Derm Venereol (2005) 0.75
[Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis: experience with six pediatric patients. Potential efficacy of methotrexate]. Rev Neurol (2013) 0.75
Prevalence of chronic rheumatic diseases in Mexico. J Rheumatol (2011) 0.75
Estimating glomerular filtration rate. N Engl J Med (2012) 0.75
Inducible nitric oxide synthase (iNOS) expression in autoimmune thyroid disorders (AITD). Endocrinol Nutr (2008) 0.75
Renal function assessment in patients with systemic lupus erythematosus. Rheumatol Int (2011) 0.75
Laboratory biomarkers for guiding therapy with methotrexate in rheumatoid arthritis. Curr Pharm Des (2015) 0.75
Lupus nephritis: advances in the knowledge of its immunopathogenesis without the expected therapeutic success? Reumatol Clin (2013) 0.75
Economic impact of estimating renal function in patients with systemic lupus erythematosus. Nefrologia (2012) 0.75
Neuropsychiatric manifestations in systemic lupus erythematosus: physiopathogenic and therapeutic basis. Reumatol Clin (2013) 0.75
Tie-2 is overexpressed by monocytes in autoimmune thyroid disorders and participates in their recruitment to the thyroid gland. J Clin Endocrinol Metab (2009) 0.75
p,p'-DDE, a DDT metabolite, induces proinflammatory molecules in human peripheral blood mononuclear cells "in vitro". Exp Toxicol Pathol (2012) 0.75
CKD-EPI is the most reliable equation to estimate renal function in patients with systemic lupus erythematosus. Nefrologia (2013) 0.75
Modified neonatal B-cell repertoire as a consequence of rituximab administration to a pregnant woman. Rheumatology (Oxford) (2012) 0.75
DDE and PCB 153 independently induce aryl hydrocarbon receptor (AhR) expression in peripheral blood mononuclear cells. J Immunotoxicol (2014) 0.75